Adverse Events Associated with Incretin-Based Therapies: A Narrative Review on Mechanisms, Clinical Management, and Risk Mitigation
Drug Design, Development and Therapy · 2026-07 · Volume 20 · 1-20
DOI: 10.2147/dddt.s622972 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drug Design, Development and Therapy, 2026-07. Verfasst von Mansour Tobaiqy und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Basic Medical Sciences, College of Medicine, University of Jeddah, Jeddah, Saudi Arabia. Hauptthemen laut MEDLINE: Incretins, Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor Agonists, Obesity. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Themen: Patientensicherheit
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Basic Medical Sciences, College of Medicine, University of Jeddah, Jeddah, Saudi Arabia.
- Department of Family and Community medicine, College of Medicine, University of Jeddah, Jeddah, Saudi Arabia.
ORCID-Profile: Mansour Tobaiqy, Sulafa Tarek Alqutub
Zitieren
APA
Tobaiqy, M., & Alqutub, S. T. (2026). Adverse Events Associated with Incretin-Based Therapies: A Narrative Review on Mechanisms, Clinical Management, and Risk Mitigation. Drug Design, Development and Therapy, Volume 20, 1-20. https://doi.org/10.2147/dddt.s622972
Vancouver
Tobaiqy M, Alqutub ST. Adverse Events Associated with Incretin-Based Therapies: A Narrative Review on Mechanisms, Clinical Management, and Risk Mitigation. Drug Design, Development and Therapy. 2026;Volume 20:1-20. doi:10.2147/dddt.s622972
BibTeX
@article{Tobaiqy2026,
author = {Tobaiqy, Mansour and Alqutub, Sulafa Tarek},
title = {Adverse Events Associated with Incretin-Based Therapies: A Narrative Review on Mechanisms, Clinical Management, and Risk Mitigation},
journal = {Drug Design, Development and Therapy},
year = {2026},
volume = {Volume 20},
pages = {1--20},
doi = {10.2147/dddt.s622972}
}
EUVIMED